Therefore, information about p-tau212 levels in preclinical studies might also help with the exclusion/inclusion criteria for clinical trials, which will include p-tau212 as a target engagement biomarker for AD therapies that indirectly target amyloid or tau pathology in AD, and an increase of this epitope might reflect a multifactorial imbalance in homeostasis. Here, MAPT is linked to Alzheimer disease.